BMC Cancer

Table 1 Clinical and Pathologic Features of Study Patients

From: The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence

		CCIH		CCF		RPCI
		Total	Her2+	Total	Her2+	Her2+
ER	N	452	69	240	81	64
	+	311	38	186	59	32
	-	135	31	42	20	28
	n/a	6	0	12	2	4
PR	+	234	20	128	30	10
	-	204	48	104	48	46
	n/a	14	1	8	3	8
Age	Mean	58	56	62	61	56
	<50	132	25	57	25	23
	> = 50	320	44	183	56	41
Nodal Stage	0	259	34	135	52	23
	1	176	32	56	16	31
	2	8	3	24	10	5
	3	0	0	8	2	3
	n/a	9	0	17	1	2
Tumor Stage	1	234	26	133	42	29
	2	168	35	83	29	22
	3	21	2	12	4	5
	4	12	4	10	5	5
	n/a	17	2	2	1	3
Clinical Stage	1	172	19	90	31	15
	2A	133	19	62	27	23
	2B	92	21	26	7	11
	3A	15	1	27	9	7
	3B	16	7	8	4	3
	3C	0	0	8	2	3
	n/a	24	2	19	1	2
Grade	1	69	5	31	7	4
	2	175	21	101	35	22
	3	162	32	72	34	35
	n/a	90	11	36	5	3
Chemo	None	250	28	115	31	18
	Adjuvant	241	41	74	22	45
	n/a	5	0	51	28	1

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com